REGN - Regeneron Ultragenyx's Evkeeza helps reduce bad cholesterol in kids 5 to 11 with rare disorder in study

Regeneron Pharmaceuticals (NASDAQ:REGN) said a phase 3 trial of Evkeeza (evinacumab) met its main goal in children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH). HoFH is a rare inherited condition and is a type of of familial hypercholesterolemia — a disorder in which it is difficult for the body to remove low-density lipoprotein-cholesterol (LDL-C), also called 'bad' cholesterol, from the blood. The company said the trial met its main goal showing children who received Evkeeza to other lipid-lowering therapies reduced their LDL-C by 48% at week 24 on average. Regeneron added that despite treatment with other lipid-lowering therapies, 14 children entered the trial with an average LDL-C level of 264 mg/dL, more than twice the target (<130 mg/dL) for children with HoFH. After 24 weeks of treatment, 79% of patients reduced their LDL-C by at least half, said the company. Regeneron noted that an absolute 132 mg/dL reduction in LDL-C from baseline,

For further details see:

Regeneron, Ultragenyx's Evkeeza helps reduce bad cholesterol in kids 5 to 11 with rare disorder in study